Skip to main
TIL
TIL logo

Instil Bio (TIL) Stock Forecast & Price Target

Instil Bio (TIL) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 20%
Hold 40%
Sell 0%
Strong Sell 0%

Bulls say

Instil Bio Inc. has experienced a significant price surge, climbing nearly 500% following the release of the full HARMONi-2 dataset, indicating strong market enthusiasm and potential for positive catalysts, particularly with upcoming data from Summit Therapeutics' ivonescimab expected in mid-2025. The company's innovative CoStAR platform for genetically engineered tumor infiltrating lymphocyte therapies is positioned to potentially expand beyond its current indications, which, while not currently modeled, could enhance valuation and growth prospects. A discounted cash flow analysis estimates Instil Bio's firm value at approximately $884 million, suggesting a strong financial foundation bolstered by their cutting-edge approach to cancer treatment through checkpoint inhibition and anti-angiogenesis strategies.

Bears say

Instil Bio Inc reported a significant net loss of $1.82 per share for the fourth quarter of 2024, which is indicative of ongoing financial challenges. Projections for the full year 2025 anticipate an even greater net loss of $11.51 per share, reflecting worsened financial expectations compared to earlier estimates of $3.65 per share. Additionally, the company faces several operational risks, including potential delays in clinical trials and the possibility of unfavorable clinical data, which may further contribute to financial instability and shareholder dilution.

Instil Bio (TIL) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 20% recommend Buy, 40% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Instil Bio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Instil Bio (TIL) Forecast

Analysts have given Instil Bio (TIL) a Buy based on their latest research and market trends.

According to 5 analysts, Instil Bio (TIL) has a Buy consensus rating as of Jul 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $73, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $73, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Instil Bio (TIL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.